281 related articles for article (PubMed ID: 25609219)
1. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
Kobayashi M; Kajiwara M; Hasegawa S
J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
[TBL] [Abstract][Full Text] [Related]
5. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
Boulenc X; Djebli N; Shi J; Perrin L; Brian W; Van Horn R; Hurbin F
Drug Metab Dispos; 2012 Jan; 40(1):187-97. PubMed ID: 22004687
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
7. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
[TBL] [Abstract][Full Text] [Related]
9. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
Hurbin F; Boulenc X; Daskalakis N; Farenc C; Taylor T; Bonneau D; Lacreta F; Cheng S; Sultan E
J Clin Pharmacol; 2012 Oct; 52(10):1506-15. PubMed ID: 22128201
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
Horenstein RB; Madabushi R; Zineh I; Yerges-Armstrong LM; Peer CJ; Schuck RN; Figg WD; Shuldiner AR; Pacanowski MA
J Clin Pharmacol; 2014 Aug; 54(8):865-73. PubMed ID: 24710841
[TBL] [Abstract][Full Text] [Related]
13. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
Duong JK; Nand RA; Patel A; Della Pasqua O; Gross AS
Pharmacol Res Perspect; 2022 Apr; 10(2):e00946. PubMed ID: 35307978
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
15. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
Ford NF
J Clin Pharmacol; 2016 Dec; 56(12):1474-1483. PubMed ID: 27196064
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial.
Hirsh-Rokach B; Spectre G; Shai E; Lotan A; Ritter A; Al-Aieshy F; Malmström RE; Varon D; Alcalai R
Pharmacotherapy; 2015 Feb; 35(2):140-7. PubMed ID: 25689244
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
18. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
[TBL] [Abstract][Full Text] [Related]
20. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
